1. Home
  2. MSEX vs GYRE Comparison

MSEX vs GYRE Comparison

Compare MSEX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSEX
  • GYRE
  • Stock Information
  • Founded
  • MSEX 1897
  • GYRE 2002
  • Country
  • MSEX United States
  • GYRE United States
  • Employees
  • MSEX N/A
  • GYRE N/A
  • Industry
  • MSEX Water Supply
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • MSEX Utilities
  • GYRE Health Care
  • Exchange
  • MSEX Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • MSEX 1.1B
  • GYRE 897.1M
  • IPO Year
  • MSEX N/A
  • GYRE N/A
  • Fundamental
  • Price
  • MSEX $56.10
  • GYRE $8.07
  • Analyst Decision
  • MSEX Buy
  • GYRE
  • Analyst Count
  • MSEX 4
  • GYRE 0
  • Target Price
  • MSEX $61.00
  • GYRE N/A
  • AVG Volume (30 Days)
  • MSEX 113.0K
  • GYRE 412.5K
  • Earning Date
  • MSEX 07-30-2025
  • GYRE 08-12-2025
  • Dividend Yield
  • MSEX 2.41%
  • GYRE N/A
  • EPS Growth
  • MSEX 18.33
  • GYRE N/A
  • EPS
  • MSEX 2.40
  • GYRE 0.02
  • Revenue
  • MSEX $195,654,000.00
  • GYRE $100,643,000.00
  • Revenue This Year
  • MSEX $9.16
  • GYRE $21.04
  • Revenue Next Year
  • MSEX $7.82
  • GYRE $89.64
  • P/E Ratio
  • MSEX $23.51
  • GYRE $100.77
  • Revenue Growth
  • MSEX 16.02
  • GYRE N/A
  • 52 Week Low
  • MSEX $48.18
  • GYRE $6.11
  • 52 Week High
  • MSEX $70.73
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • MSEX 41.30
  • GYRE 43.87
  • Support Level
  • MSEX $54.69
  • GYRE $7.99
  • Resistance Level
  • MSEX $58.02
  • GYRE $8.55
  • Average True Range (ATR)
  • MSEX 1.28
  • GYRE 0.64
  • MACD
  • MSEX 0.04
  • GYRE -0.05
  • Stochastic Oscillator
  • MSEX 37.01
  • GYRE 28.82

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: